Cellular senescence, first described in vitro in 1961, has become a focus for biotech
companies that target it to ameliorate a variety of human conditions. Eminently characterized …

Signature Cytokines and Immune-Mediated Inflammatory Diseases The ability to block
specific cytokine pathways has revealed pathophysiological differences among autoimmune …

Objective To evaluate the efficacy, including capacity for inhibition of radiographic
progression, and safety of upadacitinib, a JAK 1‐selective inhibitor, as compared to placebo …

Methotrexate (MTX) is used as an anchor disease-modifying anti-rheumatic drugs
(DMARDs) in treating rheumatoid arthritis (RA) because of its potent efficacy and tolerability …

Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international …

Chronological age represents the single greatest risk factor for human disease. One
plausible explanation for this correlation is that mechanisms that drive ageing might also …

Objective To develop a new evidence‐based, pharmacologic treatment guideline for
rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the …

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily targets
synovial joints, resulting in pain and functional limitations. It is the most common …

Abstract Tumor Necrosis Factor (TNF), initially known for its tumor cytotoxicity, is a potent
mediator of inflammation, as well as many normal physiological functions in homeostasis …

Objective We undertook this phase III study to evaluate baricitinib, an orally administered
JAK‐1/JAK‐2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to …